Abstract
AbstractA vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. Thirty-two healthy volunteers were vaccinated at least three times with MSP1 plus adjuvant, adjuvant alone, or placebo (24:4:4) to evaluate the safety and immunogenicity. MSP1 was safe, well tolerated and immunogenic, with all vaccinees sero-converting independent of the dose. The MSP1-specific IgG and IgM titers persisted above levels found in malaria semi-immune humans for at least 6 months after the last immunization. The antibodies were variant- and strain-transcending and stimulated respiratory activity in granulocytes. Furthermore, full-length MSP1 induced memory T-cells. Our findings encourage challenge studies as the next step to evaluate the efficacy of full-length MSP1 as a vaccine candidate against falciparum malaria (EudraCT 2016-002463-33).
Funder
Sumaya Biotech GmbH & Co. KG, Heidelberg, Germany and Badische Beamtenbank, Germany
Sumaya Biotech GmbH & Co. KG, Heidelberg, Germany
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference105 articles.
1. World Health Organization. World Malaria Report 2018 (WHO Press, Geneva 2018).
2. Ashley, E. A., Pyae Phyo, A. & Woodrow, C. J. Malaria. Lancet 391, 1608–1621 (2018).
3. Visser, B. J., van Vugt, M. & Grobusch, M. P. Malaria: an update on current chemotherapy. Expert Opin. Pharmacother. 15, 2219–2254 (2014).
4. Moorthy, V. S., Newman, R. D. & Okwo-Bele, J. M. Malaria vaccine technology roadmap. Lancet 382, 1700–1701 (2013).
5. World Health Organization. Global Technical Strategy for Malaria 2016–2030 (WHO Press, Geneva, 2016).
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献